Tag:
Sermo
Latest Headlines
Latest Headlines
UPDATED: Enbrel beats rivals in rheumatologist survey
With the market for rheumatoid arthritis meds set to soar, rheumatologists weighed in on the existing drugs that provide the best outcomes for patients--and Amgen's ( $AMGN ) Enbrel topped the list,
Docs blame reimbursement, complexity, cost-benefit for Provenge uptake
Dendreon ( $DNDN ) may face a lot more than cost density in persuading doctors to adopt its prostate cancer vaccine Provenge. Oncologists and urologists said reimbursement issues have contributed to
Docs like pharma dinners--with a few caveats
Marketing managers, listen up: what would bring a doctor out for a pharma-sponsored dinner meeting? Info on multiple sclerosis treatment, for one. Updates on new anti-clotting drugs, for another.
Survey: Lipitor, Plavix yield best heart-patient outcomes
The results of a survey of cardiologists could provoke tears from executives at Pfizer ( $PFE ), Sanofi ( $SNY ) and Bristol-Myers Squibb ( $BMY ). Tears of happiness, maybe--Pfizer's Lipitor and the
Pfizer 3.0 taps EHRs, mobile tech for drug safety
Pfizer must be listening to consultancy Ernst & Young. The big pharma is turning to electronic health records and mobile technology to improve its drug-safety monitoring and communication with
Pfizer wants to party with docs online
Pfizer is crashing an online party for physicians. The drug maker has inked a deal with Sermo, a sort of Facebook for docs who want to gossip about their practices--drug side effects included.
